OncoMatch/Clinical Trials/NCT05910177
Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin
Is NCT05910177 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Karelizumab combined with etoposide and cisplatin for carcinoma.
Treatment: Karelizumab combined with etoposide and cisplatin — This study is a single arm, exploratory clinical study aimed at evaluating the efficacy and safety of karelizumab combined with etoposide and cisplatin in the neoadjuvant treatment of neuroendocrine cervix carcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Disease stage
Required: Stage I, II
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy
Cannot have received: radiation therapy
Cannot have received: targeted drug therapy
Cannot have received: immunotherapy
Lab requirements
Blood counts
HB ≥ 100g/L; WBC ≥ 3 × 10^9/L; ANC ≥ 1.5 × 10^9/L; PLT ≥ 100 × 10^9/L (no blood transfusion within 14 days)
Kidney function
Serum Cr ≤ 1x ULN; endogenous creatinine clearance rate >60 ml/min (Cockcroft Goult formula)
Liver function
BIL <1.5x ULN; ALT and AST <2.5x ULN; GPT ≤ 1.5x ULN
Cardiac function
No severe heart disease; no coronary heart disease of grade I or above; no arrhythmia (including prolonged QTc interval, female >470 ms); no cardiac dysfunction; no NYHA grade II or above heart failure; no unstable angina; no myocardial infarction within 1 year; no clinically significant supraventricular or ventricular arrhythmias that are still poorly controlled
The main organs function normally and meet the following standards: ... (see above for full details)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05910177 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage I or II is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify